1018eTiP A phase I trial of RGT-61159, an oral MYB transcription factor inhibitor, for patients with relapsed/refractory (R/R) adenoid cystic carcinoma (ACC) and colorectal cancer (CRC). - Hanna, G.J.; Sanz Garcia, E.; Spira, A.I.; Hilton, J.F.; Ferrarotto, R.; Zujun, L.; Rodriguez, C.P.; Swiecicki, P.L.; Xi, S.; Soulard, P.; Wager, T.T.; Walling, J.; et al. (Annals of Oncology, 2025)